Escape hepatitis B virus mutations in recipients of antibody to hepatitis B core antigen–positive liver grafts receiving hepatitis B immunoglobulins

A variety of prophylactic strategies are used to prevent the risk of hepatitis B virus (HBV) transmission from antibody to hepatitis B core antigen (anti‐HBc)–positive donors. The mechanisms underlying the failure of HBV immunoglobulin monoprophylaxis have been poorly evaluated. Seventy‐seven anti‐HBc–positive grafts were used in 21 hepatitis B surface antigen (HBsAg)–positive recipients and 56 HBsAg‐negative recipients. HBsAg‐positive recipients received prophylaxis comprising hepatitis B immunoglobulins (HBIG) and antiviral agents, 45 HBsAg‐negative recipients received a modified HBIG regimen, and 11 HBsAg‐negative recipients received no prophylaxis. Both donors and recipients were screened for HBsAg, antibody to HBsAg (anti‐HBs) and anti‐HBc in their sera and for HBV DNA in both their sera and liver. S gene mutations were investigated after HBV reinfection. HBV infection occurred in 15 HBsAg‐negative recipients (19.4%) at a median interval of 16 months (range = 6‐67 months) post‐transplant and in none of the HBsAg‐positive recipients. HBV infections were observed in 31.6% of HBV‐naive recipients and 7.7% of HBV‐immune recipients receiving HBIG prophylaxis versus 100% of HBV‐naive recipients (P = 0.0068) and 33% of HBV‐immune recipients (P = 0.08) with no such prophylaxis. S gene mutations were identified in 9 recipients. In conclusion, priority should be given to using anti‐HBc positive grafts for HBsAg‐positive or HBV‐immune recipients. Our study has confirmed the high risk of HBV transmission to naive recipients. HBIG monoprophylaxis was associated with a significant risk of de novo HBV infection and HBV escape mutations. In these patients, we therefore recommend prophylaxis with lamivudine or new nucleos(t)ides analogues. The potential benefits of HBIG prophylaxis combined with antiviral drugs require further evaluations. Long‐term prophylaxis is needed because of the long interval of de novo HBV infection post‐transplant in some patients. Liver Transpl 16:885–894, 2010. © 2010 AASLD.

[1]  A. Burroughs,et al.  Liver grafts from anti-hepatitis B core positive donors: a systematic review. , 2010, Journal of hepatology.

[2]  T. Koepsell,et al.  Survival after orthotopic liver transplantation: The impact of antibody against hepatitis B core antigen in the donor , 2009, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[3]  M. Ho,et al.  High-Titer Antibody to Hepatitis B Surface Antigen Before Liver Transplantation Can Prevent De Novo Hepatitis B Infection , 2009, Journal of pediatric gastroenterology and nutrition.

[4]  R. Perrillo.  Hepatitis B virus prevention strategies for antibody to hepatitis B core antigen–positive liver donation: A survey of North American, European, and Asian‐Pacific transplant programs , 2009, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[5]  D. Samuel,et al.  Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. , 2008, Gastroenterology.

[6]  H. Marusawa,et al.  Beneficial Effects of Short‐Term Lamivudine Treatment for de novo Hepatitis B Virus Reactivation After Liver Transplantation , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[7]  G. McCaughan,et al.  Long‐term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface‐antigen negative liver transplant recipients from hepatitis B core‐antibody‐positive donors , 2006, Clinical transplantation.

[8]  J. Aranda‐Michel,et al.  Case Report of Lamivudine‐Resistant Hepatitis B Virus Infection Post Liver Transplantation from a Hepatitis B Core Antibody Donor , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[9]  J. Nuno,et al.  Prevention of de novo HBV infection by the presence of anti-HBs in transplanted patients receiving core antibody-positive livers. , 2006, World journal of gastroenterology.

[10]  H. Leying,et al.  Fully automated quantitation of hepatitis B virus (HBV) DNA in human plasma by the COBAS AmpliPrep/COBAS TaqMan system. , 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[11]  G. Moraleda,et al.  De Novo HBV Infection Caused by an Anti‐HBc Positive Donor in a Vaccinated Liver Transplant Recipient In Spite of Anti‐HBs Response , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[12]  U. Bienzle,et al.  Immunization with an adjuvant hepatitis B vaccine in liver transplant recipients: Antibody decline and booster vaccination with conventional vaccine , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[13]  A. Jain,et al.  Use of hepatitis B core antibody-positive liver allograft in hepatitis C virus-positive and -negative recipients with use of short course of hepatitis B immunoglobulin and Lamivudine. , 2005, Transplantation proceedings.

[14]  J. Rakela,et al.  Virologically compromised donor grafts in liver transplantation. , 2004, Journal of hepatology.

[15]  J. Joh,et al.  Prevention of de novo hepatitis B infection from HbcAb-positive donors in living donor liver transplantation. , 2004, Transplantation proceedings.

[16]  C. Gibbs,et al.  Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. , 2004, Gastroenterology.

[17]  G. Farr,et al.  Does lamivudine prophylaxis eradicate persistent HBV DNA from allografts derived from anti‐HBc‐positive donors? , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[18]  J. Crespo,et al.  Liver transplantation with allografts from hepatitis B core antibody‐positive donors: A new approach , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[19]  Roger Williams,et al.  Endocytosis of Hepatitis B Immune Globulin into Hepatocytes Inhibits the Secretion of Hepatitis B Virus Surface Antigen and Virions , 2003, Journal of Virology.

[20]  D. Samuel,et al.  HBV DNA persistence 10 years after liver transplantation despite successful anti‐HBS passive immunoprophylaxis , 2003, Hepatology.

[21]  K. Lee,et al.  Active immunization against de novo hepatitis B virus infection in pediatric patients after liver transplantation , 2003, Hepatology.

[22]  E. Schiff,et al.  Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine , 2003, Transplantation.

[23]  J. Dumortier,et al.  HBV reactivation in the recipient of a liver graft from an anti-HBc positive donor despite post-vaccination antibodies to hepatitis B surface antigen. , 2002, Journal of hepatology.

[24]  Chao-Long Chen,et al.  Prevention of de novo hepatitis B virus infection in living donor liver transplantation using hepatitis B core antibody positive donors , 2002, Clinical transplantation.

[25]  D. V. van Thiel,et al.  Use of hepatitis B core antibody-positive donors in orthotopic liver transplantation. , 2002, Archives of surgery.

[26]  D. Samuel,et al.  Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors , 2002, Gut.

[27]  S. Geller,et al.  Transmission of hepatitis B infection from hepatitis B core antibody–positive liver allografts is prevented by lamivudine therapy , 2001, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[28]  J. Córdoba,et al.  De novo hepatitis B after liver transplantation from hepatitis B core antibody—Positive donors in an area with high prevalence of anti‐HBc positivity in the donor population , 2001, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[29]  C. Scudamore,et al.  De novo acute hepatitis B infection in a previously vaccinated liver transplant recipient due to a strain of HBV with a Met 133 Thr mutation in the "a" determinant. , 2000, Liver.

[30]  N. Chalasani,et al.  Vaccination against hepatitis B in patients with chronic liver disease awaiting liver transplantation. , 1999, The American journal of the medical sciences.

[31]  J. Fung,et al.  Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. , 1999, Transplantation.

[32]  H. Marusawa,et al.  Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants. , 1998, Transplantation.

[33]  J. Fung,et al.  Infectivity of hepatic allografts with antibodies to hepatitis B virus. , 1997, Transplantation.

[34]  R. Wiesner,et al.  Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. , 1997, Gastroenterology.

[35]  D. Samuel,et al.  De novo and apparent de novo hepatitis B virus infection after liver transplantation. , 1997, Journal of hepatology.

[36]  J. Emond,et al.  The Risk Of Transmission Of Hepatitis B From Hbsag(-), Hbcab(+), Hbigm(-) Organ Donors , 1995, Transplantation.

[37]  P. Bedossa,et al.  Intraobserver and Interobserver Variations in Liver Biopsy Interpretation in Patients with Chronic Hepatitis C , 1994 .

[38]  G. Alexander,et al.  Liver transplantation in European patients with the hepatitis B surface antigen. , 1993, The New England journal of medicine.

[39]  J. Vahrman.  Transmission of hepatitis. , 1970, Lancet.